Chronic inflammatory demyelinating polyneuropathy

Neuromuscular Disorders

Volumn 6, Issue 5, 1996, Pages 311-325

  Briani, Chiara ^a   Brannagan III, Thomas H ^a   Trojaborg, Werner ^a   Latov, Norman ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN;

BACKACHE; CATARACT; CHRONIC INFLAMMATION; CLINICAL FEATURE; DEMYELINATING NEUROPATHY; DIFFERENTIAL DIAGNOSIS; ELECTROLYTE DISTURBANCE; FRACTURE; HEADACHE; HOT FLUSH; HYPERGLYCEMIA; HYPERTENSION; IMMUNE DEFICIENCY; LABORATORY DIAGNOSIS; MYALGIA; OBESITY; OSTEOPOROSIS; PLASMAPHERESIS; POLYNEUROPATHY; PRIORITY JOURNAL; REVIEW; SHIVERING; STOMACH ULCER;

EID: 0030273776     PISSN: 09608966     EISSN: None     Source Type: Journal    
DOI: 10.1016/0960-8966(96)00356-2     Document Type: Review

References (167)

1. 1. Hoestermann E. On recurring polyneuritis (in German). Dtsche Z Nervenheilkd 1914; 51: 116-123.
2. 2. Roussy G, Cornil L. Progressive hypertrophic nonfamilial neuritis in adult (in French). Ann Med 1919; 6: 206-305.
3. 3. De Jong R N. The Guillain-Barré syndrome. Polyradiculoneuritis with albuminocytologic dissociation. Arch Neurol Psychiatr 1940; 44: 1044-1068.
4. 4. Dyck P J, Lais A C, Ohta M, Bastron J A, Okazaki H, Groover R V. Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc 1975; 50: 621-637.
5. 5. Torvik A, Lundar T. A case of chronic demyelinating polyneuropathy resembling the Guillain-Barré syndrome. J Neurol Sci 1977; 32: 45-52.
6. 6. Dyck P. O'Brien P C, Oviatt K F, et al. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol 1982; 11: 136-141.
7. 7. Prineas J W, McLeod J G. Chronic relapsing polyneuritis. J Neurol Sci. 1976; 27: 427-458.
8. 8. McCombe P A, Pollard J D, McLeod J G. Chronic inflammatory demyelinating neuropathy. Brain 1987; 110: 1617-1630.
9. 9. Dalakas M C, Engel W K. Chronic relapsing (dysimmune) polyneuropathy. Pathogenesis 1981; 9: 134-145.
10. 10. Barohn R J, Kissel J T, Warmolts J R, Mendell J R. Chronic inflammatory demyelinating polyneuropathy. Clinical characteristics, course, and recommendations for diagnostic criteria. Arch Neurol 1989; 46: 878-884.
11. 11. Verma A, Tandan R, Adesina A M, Pendlebury W W, Fries T J, Bradley W G. Focal neuropathy preceding chronic inflammatory demyelinating polyradiculoneuropathy by several years. Acta Neurol Scand 1990; 81: 516-521.
12. 12. Donaghy M, Earl C J. Ocular palsy preceding chronic relapsing polyneuropathy by several weeks. Ann Neurol 1985; 17: 49-50.
13. 13. Austin J K. Recurrent polyneuropathies and their corticosteroid treatment with five years observation on a placebo controlled case treated with corticotrophin, cortisone and prednisone. Brain 1958; 81: 157-192.
14. 14. Thomas P K, Lascelles R G, Hallpike J F, Hewer R L. Recurrent and chronic relapsing Guillain-Barré polyneuritis. Brain 1969; 92: 589-606.
15. 15. Ropper A H, Wijdicks E F M, Traux B T. Guillain-Barré syndrome. Philadelphia: FA Davis, 1991.
16. 16. Simmons Z, Albers J W, Bromberg M B, Feldman E L. Presentation and initial course in patients with chronic inflammatory demyelinating polyradiculoneuropathy: comparison of patients without and with monoclonal gammopathy. Neurology 1993; 43: 2202-2209.
17. 17. McCombe P A, McManis P G, Frith J A, Pollard J D, McLeod J G. Chronic inflammatory demyelinating neuropathy associated with pregnancy. Ann Neurol 1987; 21: 102-104.
18. 18. Joy J L, Oh S J. Sensory neuropathy as a variant of chronic inflammatory demyelinating neuropathy. Neurology 1988; 38(suppl 1): 189.
19. 19. Cros D, Chiappra K H, Patel S, Gominak S. Acquired pure sensory demyelinating polineuropathy: a chronic inflammatory polyradiculoneuropathy variant? Ann Neurol 1992; 32: 280.
20. 20. Ropper A H, Weinberg D. Chronic immune demyelinating polyneuropathy (CIDP). Neurol Chron 1992; 1: 1-8.
21. 21. Berger A R, Herskovitz S. Kaplan J. Late motor involvement in cases presenting as "chronic sensory demyelinating polyneuropathy". Muscle Nerv 1995; 18: 440-444.
22. 22. Oh S J, Joy J L, Kurouglu R. Chronic sensory demyelinating neuropathy: chronic inflammatory demyelinating polyneuropathy presenting as a pure sensory neuropathy. J Neurol Neurosurg Psychiatr 1992; 55: 677-680.
23. 23. Rubin M, Karpati G, Carpenter S. Combined central and peripheral myelinopathy. Neurology 1987; 37: 1287-1290.
24. 24. Thomas P K, Walker R W H, Rudge P, et al. Chronic demyelinating peripheral neuropathy associated with multifocal CNS demyelination. Brain 1987; 110: 53-76.
25. 25. Mendell J R, Kolkin S, Kissel J T, Weiss K L, Chakares D W, Rammohan K W. Evidence for central nervous sytem demyelination in chronic inflammatory polyradiculoneuropathy. Neurology 1987; 37: 1291-1294.
26. 26. Pakalnis A, Drake M E, Barohn R J, Chakeres D W, Mendell J R. Evoked potentials in chronic inflammatory demyelinating polyneuropathy. Arch Neurol 1988; 45: 1014-1016.
27. 27. Feasby T E, Hahn A F, Koopman W J, Lee D H. Central lesions in chronic inflammatory demyelinating polyneuropathy: an MRI study. Neurology 1990; 40: 476-478.
28. 28. Hawke S H, Hallinan J M, McLeod J G. Cranial magnetic resonance imaging in chronic demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 1990; 53: 794-796.
29. 29. Ormerod J E C, Waddy H M, Kermonde A G, et al. Involvement of the central nervous system in chronic inflammatory demyelinating polyneuropathy: a clinical, electrophysiological and magnetic resonance imaging study. J Neurol Neurosurg Psychiatr 1990; 53: 789-793.
30. 30. Uncini A, Gallucci M, Lugaresi A, Porrini A M, Onofrj M, Gambi D. CNS involvement in chronic inflammatory demyelinating polyneuropathy: an electrophysiological and MRI study. Electromyogr Clin Neurophysiol 1991; 31: 365-371.
31. 31. Cornblath D R, McArthur J C, Kennedy P G E, Witte A S, Griffin J W. Inflammatory demyelinating neuropathies associated with human T-cell lymphotropic virus type III infection. Ann Neurol 1987; 21: 32-40.
32. 32. Ghika-Schmid F, Kuntzer T, Chave J P, Miklossy J, Regli F. Range of neuromuscular involvement in 47 patients infected with the human immunodeficient virus (in French). Schweiz Medizin Wochenschr J Suisse Med 1994; 124: 791-800.
33. 33. Bleasel A F, Hawke S H, Pollard J D, McLeod J G. IgG monoclonal paraproteinemia and peripheral neuropathy. J Neurol Neurosurg Psychiatr 1993; 56: 52-57.
34. 34. Dyck P J, Swanson P A, Low P A, Bartleson J D, Lambert E H. Prednisone responsive hereditary motor and sensory neuropathy. Mayo Clin Proc. 1982; 57: 239-246.
35. 35. Byers R K, Taft L T. Chronic multiple peripheral neuropathy in childhood. Pediatrics 1957; 20: 517-537.
36. 36. Tasker W, Chutorian A M. Chronic polyneuritis of childhood. J Pediatr 1969; 74: 699-708.
37. 37. Low N, Schneider J, Carter S. Polyneuritis in children. Pediatrics 1958; 22: 972-990.
38. 38. Colan R V, Snead O C, Oh S J, Benton J W, Jr. Steroid-responsive polyneuropathy with subacute onset in childhood. J Pediatr 1980; 97: 374-377.
39. 39. Pasternak J F, Fulling K, Nelson J, Prensky A L. An infant with chronic, relapsing polyneuropathy responsive to steroids. Dev Med Child Neurol 1982; 24: 504-510.
40. 40. Gabreels-Festen A A, Hageman A T, Gabreels F J, et al. Chronic inflammatory demyelinating polyneuropathy in two siblings. J Neurol Neurosurg Psychiatry 1986; 49: 152-156.
41. 41. Faleck H, Cruse R P, Levin K H, Estes M. Response of CSF IgG to steroids in an 18-month old with chronic inflammatory polyradiculoneuropathy. Cleve Clin J Med 1989; 56: 539-541.
42. 42. Wakai S, Watanabe Y, Ichiki T, et al. Childhood multiple sclerosis: MR images and clinical variations in four Japanese cases. Brain Dev 1994; 16: 52-56.
43. 43. Sladky J T. Neuropathy in childhood. Semin Neurol 1987; 7: 67-75.
44. 44. Beydoun S R, Engel W K, Karofsky P, Schwarts M U. Long-term plasmapheresis therapy is effective and safe in children with chronic relapsing dysimmune polyneuropathy. Rev Neurol (Paris) 1990; 146: 123-127.
45. 45. Vedanarayanan V, Kandt R S, Lewis D V, DeLong G R. Chronic inflammatory demyelinating polyneuropathy of childhood. Treatment with high-dose intravenous immunoglobulin. Neurology 1991; 41: 828-830.
46. 46. Dalakas M C, Houff S A, Engel W K, Madden D L, Sever J L. CSF "monoclonal" bands in chronic relapsing polyneuropathy. Neurology 1980; 30: 864-867.
47. 47. Segurado O G, Kruger H, Mertens H G. Clinical significance of serum and CSF findings in the Guillain-Barré syndrome and related disorders. J Neurol 1986; 233: 202-208.
48. 48. Ilyas A A, Mithen F A, Dalakas M C. Antibodies to acidic glycolipids in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 1992; 107: 111-121.
49. 49. Khalili-Shirazi A, Atkinson P, Gregson N, Hughes R A C. Antibody responses to Po and P2 myelin proteins in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy. J Neuroimmunol 1993; 46: 245-252.
50. 50. Connolly A M, Pestronk A, Trotter J L, Feldman E L, Cornblath D R, Olney R K. High-titer selective serum anti-tubulin antibodies in chronic inflammatory demyelinating polyneuropathy. Neurology 1993; 43: 557-562.
51. 51. van Schaik I N, Vermeulen M, van Doorn P A, Brand A. Anti-β-tubulin antibodies have no diagnostic value in patients with chronic inflammatory demyelinating polyneuropathy. J Neurol 1995; 242: 599-603.
52. 52. Manfredini E, Nobile-Orazio E, Allaria S, Scarlato G. Anti alpha and beta tubulin IgM antibodies in dysimmune neuropathies. J Neurol Sci 1996; in press.
53. 53. Small G A, Lovelace R E. Chronic inflammatory demyelinating polyneuropathy. Semin Neurol 1993; 13: 305-312.
54. 54. Brown W F. Acute and chronic inflammatory demyelinating neuropathies. In: Brown W F, Bolton C F, eds. Clinical Electromyography, 2nd edn, Boston: Butterworth Heinemann, 1993.
55. 55. Koles Z J, Rasminsky M. A computer simulation of conduction in demyelinated nerve fibers. J Physiol 1972; 227: 351-364.
56. 56. Cornblath D R, Sumner A J. Conduction block in neuropathies with necrotizing vasculitis. Muscle Nerve 1991; 13: 186.
57. 57. Rhee R K, England J D, Sumner A J. A computer simulation of conduction block: effects produced by actual block versus interphase cancellation. Ann Neurol 1990: 28: 146-156.
58. 58. Fraser J L. Olney R K. The relative diagnostic sensitivity of different F-waves parameters in various polyneuropathies. Muscle Nerv 1992; 15: 912-918.
59. 59. Fisher M A. H reflexes and F waves: physiology and clinical indications. Muscle Nerve 1992; 15: 1223-1233.
60. 60. Oh S J. Subacute demyelinating polyneuropathy responding to corticosteroid treatment. Arch Neurol 1978; 35: 509-516.
61. 61. Wilbourn A J. Differentiating acquired from familial demyelinating neuropathies by EMG. Electroencephalogr Clin Neurophysiol 1977; 43: 616.
62. 62. Krarup C, Trojaborg W. Sensory pathophysiology in chronic acquired demyelinating neuropathy. Brain 1996; 19: 257-270.
63. 63. Dyck P J, Daube J, O'Brien P C, et al. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropahty. N Engl J Med 1986; 314: 461-465.
64. 64. Chaudhry V, Corse A M, Cornblath D R, Kuncl R W, Freimer M L, Griffin J W. Multifocal motor neuropathy: electrodiagnostic features. Muscle Nerve 1994; 17: 198-205.
65. 65. Rosenblum W I, Budzilovich G, Feigin. Lesions of the spinal cord in polyradiculoneuropathy of unknown aetiology and possible relationship with the Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 1966; 29: 69-76.
66. 66. Ad hoc Subcomittee of the American Academy of Neurology AIDS Task Force. Research criteria for the diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Neurolog 1991; 41: 617-618.
67. 67. Hughes R, Sanders E, Hall S, Atkinson P, Colchester A, Payan P. Subacute idiopathic demyelinating polyradiculoneuropathy. Arch Neurol 1992; 49: 612-616.
68. 68. Kelly J J. The electrodiagnostic findings in polyneuropathies associated with monoclonal gammopathy. Muscle Nerve 1983; 6: 504-509.
69. 69. Albers J W, Kelly J. J. Acquired inflammatory demyelinating polyneuropathies: clinical and electrodiagnostic features. Muscle Nerve 1989; 12: 435-451.
70. 70. Buchthal F, Behse F. Peroneal muscular atrophy (PMA) and related disorders. I. Clinical manifestation as related to biopsy findings, nerve conduction and electromyography. Brain 1977; 100: 41-66.
71. 71. Dyck P, Prineas J, Pollard J. Chronic inflammatory demyelinating polyneuropathy. In: Dyck P, et al., eds. Peripheral Neuropathy, 3rd edn. Philadelphia: WB Saunders, 1993; 1498-1517.
72. 72. Bromberg M B. Comparison of electrodiagnostic criteria for primary demyelination in chronic polyneuropathy. Muscle Nerve 1991; 14: 968-976.
73. 73. Logigian E L, Kelly J J, Adelman L S. Nerve conduction and biopsy correlation in over 100 consecutive patients with suspected polyneuropathy. Muscle Nerve 1994; 17: 1010-1020.
74. 74. Logigian E L, Kelly J J. Nerve conduction and biopsy correlation in over 100 consecutive patients with suspected polyneuropathy. Muscle Nerve 1995; 18: 1079-1080.
75. 75. Chroni E, Hall S M, Hughes R A C. Chronic relapsing axonat neuropathy: a first case report. Ann Neurol 1995; 37: 112-115.
76. 76. Uncini A, Sabatelli M, Mignogna T, Lugaresi A, Liguori R, Montagna P. Chronic progressive steroid responsive axonal polyneuropathy: a CIDP variant or a primary axonal disorder? Muscle Nerve 1996; 19: 365-371.
77. 77. Lewis R A, Sumner A J. The electrodiagnostic distinctions between chronic familial and acquired demyelinative neuropathies. Neurology 1982; 32: 592-596.
78. 78. Felice K, Poole R M, Blaivas M, Albers J W. Hereditary neuropathy with liability to pressure palsies masquerading as slowly progressive polyneuropathy. Eur Neurol 1994; 34: 173-176.
79. 79. Uncini A, Di Guglielmo G, Di Muzio A, et al. Differential electrophysiological features of neuropathies associated with 17p11.2 deletion and duplication. Muscle Nerve 1995; 18: 628-635.
80. 80. Bosch E P, Chui H C, Martin M A, Cancilla P A. Brachial plexus involvement in familial pressure-sensitive neuropathy: electrophysiological and morphological findings. Ann Neurol 1980; 8: 620-624.
81. 81. Behse F, Buchthal F, Carlsen F, Knappeis G G. Hereditary neuropathy with liability to pressure palsies. Electrophysiological and histopathological aspects. Brain 1972; 95: 777-794.
82. 82. Chance P F, Reilly M. Inherited neuropathies. Curr Opin Neurol 1994; 7: 372-380.
83. 83. Mariman E C M, Gabreels-Festen A A W M, van Beersum S E C, et al. Prevalance of the 1.5 Mb 17p deletion in families with hereditary neuropathy with liability to pressure palsies. Ann Neurol 1994; 36: 650-655.
84. 84. Nicholson G A, Valentijn L J, Cherryson A K, et al. A frame shift mutation in the PMP 22 gene in hereditary neuropathy with liability to pressure palsies. Nature Genet 1994; 6: 263-266.
85. 85. Ionasescu V V. Charcot-Marie-Tooth neuropathies: from clinical description to molecular genetics. Muscle Nerve 1995; 18: 267-275.
86. 86. Latov N, Hays A P, Sherman W H. Peripheral neuropathy and anti-MAG antibodies. CAC Crit Rev Neurobiol 1988; 3: 301-332.
87. 87. Nobile-Orazio E, Marmiroli P. Baldini L, et al. Peripheral neuropathy in macroglobulinemia: incidence and antigen-specificity of M proteins. Neurology 1987; 37: 1506-1514.
88. 88. Kelly J J. The electrodiagnostic findings in polyneuropathies associated with IgM monoclonal gammopathies. Muscle Nerve 1990; 13: 1113-1117.
89. 89. Kaku D A, England J D, Sumner A J. Distal accentuation of conduction slowing in polyneuropathy associated with antibodies to myelin-associated glycoprotein and sulphated paragloboside. Brain 1994; 117: 941-947.
90. 90. Trojaborg W, Hays A P, van den Berg L, Younger D S, Latov N. Motor conduction parameters in neuropathies associated with anti-MAG antibodies and other types of demyelinating and axonal neuropathies. Muscle Nerve 1995; 18: 730-735.
91. 91. Amato A A, Gronseth G S, Callerame K J, Kagan-Hallet K S, Bryan W W, Barohn R J. Tomaculous neuropathy a clinical and electrophysiological study in patients with and without 1.5 Mb deletions in chromosome 17p11.2. Muscle Nerve 1996; 19: 16-22.
92. 92. van den Berg L, Hays A P, Nobile-Orazio E, et al. Anti-MAG and anti-SPG antibodies in neuropathy. Muscle Nerve 1996; in press.
93. 93. Parry G J, Clarke S. Multifocal acquired neuropathy masquerading as motor neuron disease. Muscle Nerve 1988; 11: 103-107.
94. 94. Krarup C, Stewart J D, Sumner A J, Pestronk A, Lipton S A. A syndrome of asymmetrical limb weakness and motor conduction block. Neurology 1990; 40: 118-127.
95. 95. Lange D J, Trojaborg W, Latov N, et al. Multifocal motor neuropathy with conduction block: is it a distinct clinical entity? Neurology 1992; 42: 497-505.
96. 96. Pestronk A, Cornblath D R. Ilyas A A, et al. A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Ann Neurol 1988; 24: 73-78.
97. 97. Kinsella L J, Lange D J, Trojaborg W, Sadiq S A, Younger D S, Latov N. Clinical and electrophysiological correlates of elevated anti-GM1 antibody titers. Neurology 1994; 44: 1278-1282.
98. 97a. Donaghy M, Mills K R, Boniface S J, Simmons J, Wright I, Gregson N, Jacobs J. Pure motor demyelinating neuropathy; deterioration after steroid treatment and improvement with intravenous immunoglobulins. J Neurol Neurosurg Psychiat 1994; 57: 778-783.
99. 98. Ilyas A A, Quartes R H, Dalakas M C, Fishman P H, Brady R O. Monoclonal IgM in a patient with paraproteinemic neuropathy binds to gangliosides containing disialosyl groups. Ann Neurol 1985; 18: 655-659.
100. 99. Yuki N, Miyatani N, Sato S, et al. Acute relapsing sensory neuropathy associated with IgM antibody against B-series gangliosides containing disialosyl configuration. Neurology 1992; 42: 686-689.
101. 100. Willison H J, Paterson G, Veitch J, Inglis G, Barnett S C. Peripheral neuropathy associated with monoclonal IgM anti-Pr2 cold agglutinins. J Neurol Neurosurg Psychiatr 1993; 56: 1178-1184.
102. 101. Brindel I, Preud'Homme J, Vallat J, Vincent D, Vasquez J, Jauberteau M. Monoclonal IgM reactive with several gangliosides in a chronic relapsing neuropathy. Neurosci Lett 1994; 181: 103-106.
103. 102. Matthews W B, Howell D A, Hughes R A C. Relapsing corticosteroid dependent polyneuritis. J Neurol Neurosurg Psychiatr 1970; 33: 330-337.
104. 103. De Vivo D C, Engel W K. Remarkable recovery of a steroid responsive recurrent polyneuropathy. J Neurol Neurosurg Psychiatr 1970; 33: 62-69.
105. 104. Dolman C L, Allan B M. Relapsing hypertrophic neuritis. Arch Neurol 1973; 28: 351-353.
106. 105. Sladky J T, Brown M J, Berman P H. Chronic inflammatory demyelinating polyneuropathy of infancy: a corticosteroid-responsive disorder. Ann Neurol 1986; 20: 76-81.
107. 106. Schwartzman R J, Engel W K. Criteria for prednisone treatment of idiopathic polyneuropathy. Neurology 1977; 364: GS21.
108. 107. Talar-Williams C, Sneller M C. Complications of corticosteroid therapy. Eur Arch Otorhinolaryngol 1994; 258: 131-136.
109. 108. Thornton C A, Griggs R. Plasma exchange and intravenous immunoglobulins treatment of neuromuscular disease. Ann Neurol 1994; 35: 260-268.
110. 109. Keller A J, Urbaniak S J. Intensive plasma exchange on the cell separator: effect on serum immunoglobulins and complement components. Br J Haematol 1978; 38: 531-540.
111. 110. Levy R L, Newkirk R, Ochoa J. Treating chronic relapsing Guillain-Barré syndrome by plasma exchange. Lancet 1979: 2: 259-260.
112. 111. Server A C, Lefkowith J, Braine H, McKhan E M. Treatment of chronic relapsing neuropathy by plasma exchange. Ann Neurol 1979; 6: 258-261.
113. 112. Fowler H, Vulpe M, Marks G, Egolf C, Dau P C. Recovery from chronic progressive polyneuropathy after treatment with plasma exchange and cyclophosphamide. Lancet 1979; 2: 1193.
114. 113. Toyka K V, Augspach R, Paulus W, Grabensee B, Hein D. Plasma exchange in polyneuropathy. Ann Neurol 1980; 8: 205-206.
115. 114. Cook J D, Tindall R A S, Walker J. Plasma exchange as a treatment of acute and chronic idiopathic autoimmune polyneuropathy: limited success. Neurology 1980; 30: 361-362.
116. 115. Gross M L P, Thomas P K. The treatment of acute and chronic relapsing and chronic progressive idiopathic inflammatory polyneuropathy by plasma exchange. J Neurol Sci 1981; 52: 69-78.
117. 116. Bromberg M B, Feldman E L, Jaradem S, Albers J W. Prognosis in long-term immunosuppressive treatment of refractory chronic inflammatory demyelinating polyradiculoneuropathy. J Clin Epidemid 1992; 45: 47-52.
118. 117. Feasby T E, Hahn A, Brown W. Long-term plasmapheresis in chronic progressive demyelinating polyneuropathy. Ann Neurol 1983; 14: 122.
119. 118. Karmochkine M, Bussel A, Leon A, Jarrousse B, Baudelot J, Guillevin L. Long-term plasma exchange. Analysis of indications, outcome and side effects. Ann Med Interne 1994; 145: 373-375.
120. 119. Rodnitzky R L, Goeken J A. Complications of plasma exchange in neurological patients. Arch Neurol 1982; 39: 350-354.
121. 120. Mokrzycki M H, Kaplan A A. Therapeutic plasma exchange: complications and management. Am J Kidney Dis 1994; 23: 817-827.
122. 121. Vermeulen M, van der Meché F G A, Speelman J D, Weber A, Busch H F M, Plasma and gammaglobulin in chronic inflammatory polyneuropathy. J Neurol Sci 1985; 70: 317-326.
123. 122. Curro Dossi B, Tezzon F. High-dose intravenous gammaglobulin for chronic inflammatory demyelinating polyneuropathy. Ital J Neurol Sci 1987; 8: 321-326.
124. 123. Faed J M, Day B, Pollock M, et al. High-dose intravenous human immunoglobulin in chronic inflammatory demyelinating polyneuropathy. Neurology 1989; 39: 422-425.
125. 124. van Doorn P A, Vermeulen M, Brand A, Mulder P G H, Busch H F M. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy. Clinical and laboratory characteristics associated with improvement. Arch Neurol 1991; 48: 217-220.
126. 125. Cornblath D R, Chaudhry V, Griffin J W. Treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulin. Ann Neurol 1991; 30: 104-106.
127. 126. Azulay J P H, Pouget J, Pellissier J F, Blin O, Serratrice G. Chronic polyradiculoneuritis: 25 cases (in French). Rev Neurol (Paris) 1992; 148: 752-761.
128. 127. van Doorn P A, Brand A, Strengers P F W, Meulstee J, Vermeulen M. High dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind placebo controlled cross-over study. Neurology 1990; 40: 209-212.
129. 128. Vermeulen M, van Doorn P A, Brand A, Strengers P F W, Jennekens F G I, Busch H F M. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo controlled study. J Neurol Neurosurg Psychiatr 1993; 56: 36-39.
130. 129. Hahn A F, Bolton C F, Vandervoort P, Feasby T E, Zochodne D. Intravenous immunoglobulin treatment (IV IG) in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): a double-blind, placebo controlled, crossover study. Neurology 1995; 45 (suppl): A416.
131. 130. Dalakas M C, Illa I, Dambrosia J M, et al. High-dose intravenous immunoglobulin infusions as treatment for dermatomyositis. N Engl J Med 1993; 329: 1993-2000.
132. 131. Dyck P J, Litchy W J, Kratz K M, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 1994; 36: 838-845.
133. 132. Newberger J W, Takahasi M, Besier A S, et al. A single intravenous infusion of gammaglobulin as compared with four infusions in the treatment of Kawasaki syndrome. N Engl J Med 1991; 324: 1633-1639.
134. 133. Reinhart W H, Berchtold P E. Effect of high dose intravenous immunoglobulin therapy on blood rheology. Lancet 1992; 339: 662-664.
135. 134. Dalakas M C. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology 1994; 44: 223-226.
136. 135. van der Meché F G, van Doorn P A. Guillain-Barré Syndrome and chronic inflammatory demyelinating polyneuropathy: immune mechanisms and update on current therapies. Ann Neurol 1995; 37(S1): S14-S31.
137. 136. Basta M, Dalakas M C. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with determatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest. 1994; 94: 1729-1735.
138. 137. Marchalonis J J, Kaymaz H, Dedeoglu F, Schlutter S F, Yocum D E, Edmudson A B. Human autoantibodies reactive with synthetic autoantigens from T-cell receptor chain. Proc Natl Acad Sci USA 1992; 89: 3325-3327.
139. 138. Abe Y, Miyake M, Kimura S. Anti-cytokine nature of natural human immunoglobulin: one possible mechanism of the clinical effect of intravenous immunoglobulin therapy. Immun Rev 1994; 139: 5-19.
140. 139. Andersson Y, Bjork L, Skansen-Saphiri Y, Andersson J. Pooled human IgG modulates cytokine production in lymphocytes and monocytes. Immun Rev 1994; 139: 21-42.
141. 140. Debré M, Bonnet M C, Fridman W H, et al. Infusion of Fc gamma fragments for treatment of children with acute thrombocytopenic purpura. Lancet 1993; 342: 945.
142. 141. Vermeulen M, van Schaik I N, Brand A. Anti-D immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatr 1995; 58: 383-384
143. 142. Duhem C, Dicato M A, Ries F. Side-effects of intravenous immunoglobulins. Clin Exp Immunol 1994; 97(suppl 1): 79-83.
144. 143. Tan E, Hajinazarian M, Bay W, et al. Acute renal failure resulting from intravenous immunoglobulin therapy. Arch Neurol 1993; 50: 137-139.
145. 144. Brannagan T H, Nagle K J, Lange D J, Rowland L P. Complications of intravenous immune globulin (IVIG) therapy in neurologic patients. Neurology 1995; 45: 264P.
146. 145. Nemni R, Amadio S, Fazio R, Galardi G, Previtali S, Comi G. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating neuropathy not responsive to other treatments. J Neurol Neurosurg Psychiatr 1994; 57 (suppl): 43-45.
147. 146. Berger A R, Herskovitz S, Scelsa S. The restoration of IVIg efficacy by plasma exchange in CIDP. Neurology 1995; 45: 1628-1629.
148. 147. Palmer K N Y. Polyradiculoneuropathy treated with cytotoxic drugs. Lancet 1966: 1: 265.
149. 148. Cendrowski W. Treatment of polyneuropathy with azathioprine and adrenal steroids. Acta Med Pol 1977; 18: 147-156.
150. 149. Prusinski A, Szulc-Kuberska J, Zawadzki Z. A case of chronic Guillain-Barré syndrome treated successfully with azathioprine. Wiad Lek 1978; 31: 1545-1547.
151. 150. Walker G L. Progressive polyradiculoneuropathy: treatment with azathioprine. Aust NZ J Med 1979; 9: 184-187.
152. 151. Pentland B, Adams G G W, Mawdsley C. Chronic idiopathic polyneuropathy treated with azathioprine. J Neurol Neurosurg Psychiat 1982; 45: 866-869.
153. 152. Dyck P J, O'Brien P, Swanson C, et al. Combined azathioprine and prednisone in chronic inflammatory demyelinating polyneuropathy. Neurology 1985; 35: 1173-1176.
154. 153. Kissel J T, Levy R J, Mendell J R, Griggs R C. Azathioprine toxicity in neuromuscular disease. Neurology 1986; 36: 35-39.
155. 154. Silman A J, Petrie J, Hazleman B, Evans S. Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20-year follow-up study. Ann Rheum Dis 1988; 47: 988-992.
156. 155. Koski C L. Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy: pathogenesis and treatment. Semin Neurol 1994; 14: 123-130.
157. 156. Ahmed A R, Hombal S M. Cyclophosphamide (Cytoxan). A review on relevant pharmacology and clinical uses. J Am Acad Derm 1984; 11: 1115-1126.
158. 157. Boitard C, Bach J F. Long-term complications of conventional immunosuppressive treatment. Adv Nephrol 1989; 18: 335-354.
159. 158. Kolkin S, Nahman N S, Jr., Mendell J R. Chronic nephrotoxicity complicating cyclosporine treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 1987; 37: 147-149.
160. 159. Hodgkinson S J, Pollard J D, McLeod J G. Cyclosporin A in the treatment of chronic demyelinating polyradiculopathy. J Neurol Neurosurg Psychiatr 1990; 53: 327-330.
161. 160. Cockburn I. Assessment of the risks of malignancy and lymphomas developing in patients using Sandimmune. Transplant Proc 1987; 19: 1804-1807.
162. 161. Engel W K, Cuneo R A, Levy H B. Polyinosinicpolycytidylic acid treatment of neuropathy. Lancet 1978; 1: 503-504.
163. 162. Sabatelli M, Mignogna T, Lippi G, et al. Interferon alpha may benefit steroid unresponsive chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatr 1995; 58: 638-639.
164. 163. Choudhary P P, Thompson N, Hughes R A C. Improvement following interferon beta in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol 1995; 242: 252-253.
165. 164. Keating M J, O'Brien S, Kantarjian N, et al. Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood 1993; 81: 2878-2884.
166. 165. Sherman W H, Latov N, Lange D J, Hays A P, Younger D. Fludarabine for IgM antibody mediated neuropathies. Ann Neurol 1994; 36: 326.
167. 166. Rosenberg N L, Lacy J R, Kennaugh R C, Holers V M, Neville H E, Kotzin B L. Treatment of refractory chronic demyelinating polyneuropathy with lymphoid irradiation. Muscle Nerve 1985; 8: 223-232.